Bispecific gp100 peptide-HLA-A*02:01-targeted T cell engager, delivered via intravenous injection for HLA-A*02:01-positive uveal melanoma. Employed in advanced cancer care settings, obtained from immunotherapy developers and distributed to specialized oncology providers.